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Abstract
Introduction: The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia
criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a
useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheimer’s disease (AD)
in MCI based on AD biomarkers (prodromal AD/MCI due to AD). The aim of this study was to investigate the
attitudes of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due to AD criteria. We
also investigated whether the prodromal AD/MCI due to AD criteria impacted management of MCI patients.
Methods: An online survey was performed in 2015 among 102 members of the European Academy of
Neurology (EAN) and the European Alzheimer’s Disease Consortium (EADC). Questions were asked on how
often criteria were used, how they were operationalized, how they changed patient management, and what
were considered advantages and limitations of MCI and prodromal AD/MCI due to AD. The questionnaire
consisted of 47 questions scored on a Likert scale.
Results: Almost all respondents (92%) used the MCI diagnosis in clinical practice. Over 80% of the EAN/EADC
respondents found a MCI diagnosis useful because it helped to label the cognitive problem, involve patients
in planning for the future, and start risk reduction activities. These findings were similar to those reported in
the AAN survey. Research criteria for prodromal AD/MCI due to AD were used by 68% of the EAN/EADC
respondents. The most common reasons to use the criteria were increased certainty of diagnosis (86%),
increased possibilities to provide counseling (51%), facilitation of follow-up planning (48%), start of medical
intervention (49%), and response to patients’ wish for a diagnosis (41%). Over 70% of the physicians considered that a
diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis.
Conclusions: The diagnostic criteria of MCI and prodromal AD/MCI due to AD are commonly used among EAN/EADC
members. The prodromal AD/MCI due to AD were considered clinically useful and impacted patient management and
communication.
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Introduction
The term mild cognitive impairment (MCI) was origin-
ally developed for research in non-demented patients
with objective memory impairment. These subjects were
assumed to be at an increased risk of developing demen-
tia, in particular Alzheimer-type dementia [1–4]. A sur-
vey among members of the American Academy of
Neurology (AAN) showed that MCI was a common
diagnosis and considered useful [5]. However, little is
known about the clinical use of MCI outside Northern
America, where attitudes towards MCI may be different.
Moreover, since the introduction of the MCI concept,
research criteria have been proposed to diagnose Alzhei-
mer’s disease (AD) among subjects with MCI, referred
to as prodromal AD and MCI due to AD [6, 7]. These
criteria require, in addition to a diagnosis of MCI, the
presence of biomarkers indicative for AD pathophysi-
ology. Research criteria for prodromal AD were pro-
posed by an International Working Group (IWG), and
criteria for MCI due to AD by the National Institute on
Aging–Alzheimer’s Association (NIA-AA). According to
the IWG-1 criteria, prodromal AD is defined by abnor-
mal amyloid, tau, or FDG-PET or by hippocampal atro-
phy, while according to IWG-2 criteria, prodromal AD
is defined by abnormal beta amyloid 1–42 and tau in
cerebrospinal fluid (CSF) or an abnormal amyloid PET
scan [7, 8]. NIA-AA MCI due to AD is diagnosed with
high likelihood in the presence of both abnormal amyl-
oid and neuronal injury markers, and with intermediate
likelihood, in case only an amyloid or injury marker is
measured and this marker is abnormal [6]. Although
these criteria are intended for research, they are also
used in clinical practice [9]. However, it is unknown
how often these criteria are used, how they are imple-
mented, what is communicated to patients, how it af-
fects the management of patients, and what are
considered advantages and disadvantages of the criteria
relative to the MCI diagnosis. Information on how MCI
and the research criteria are perceived and used is crit-
ical for the development and implementation of guide-
lines for MCI in clinical practice, and to develop
procedures to enable international standardization.
The survey on MCI among members AAN was per-
formed in 2010. It showed that the term MCI was fre-
quently used. Perceived benefits of the use of MCI included
that the diagnosis facilitated planning for the future, moti-
vated risk reduction activities, and financial planning.
Drawbacks for using the term MCI were the difficulty to
diagnose it and the fact that a diagnosis could cause un-
necessary worry and that MCI could better be described as
early Alzheimer’s disease (AD). Despite these critics, the
benefits were thought to outweigh the drawbacks.
The aim of the present study was first to apply the
AAN questionnaire to clinicians in Europe. The survey
assessed the frequency of the use of the MCI diagnosis,
implications for communication with and management
of patients meeting criteria, and perceived strengths and
limitations of the MCI concept. Secondly, we assessed
the attitude towards the use of the preclinical AD/MCI
due to AD criteria. We asked on the frequency of use of
these criteria, how they were operationalized, what were
reasons to use the criteria or not in clinical practice,
whether a diagnosis of prodromal AD/MCI due to AD
impacted patient management compared to MCI patient
that did not meet prodromal AD/MCI due to AD cri-
teria, and whether they provided added value over the
MCI diagnosis without biomarkers.
Methods
We conducted a European multicenter survey regarding
the usefulness of MCI and prodromal AD/MCI due to
AD in clinical practice (see Additional file 1), based on
an adapted version of the MCI survey of Roberts and
colleagues [5].
Survey development and contents
The first part of the survey was on MCI with sections on
“terms and definitions,” “current practice,” and “atti-
tudes” towards the use of the criteria in clinical practice.
This part consisted of 26 questions scored on a Likert
scale. It was the same as the AAN questionnaire with a
few changes. We added questions on diagnostic investi-
gations performed in patients with MCI and counseling
on alcohol intake. We also rephrased the question on
the disease codings according to European classification
systems. In the second part of the survey, we explored
attitudes towards criteria for prodromal AD/MCI due to
AD. The format of the questions was similar to part 1,
except that we added 2 questions on possible benefits
(selection patients for trials, planning for follow-up) and
deleted the statement “MCI is usually better described
as early AD.” A steering group with both European and
American representatives evaluated the survey content
and the appropriateness of adjustments made. We pilot
tested the survey in our center to check how much time
it would take and if there were any suggestions. Next,
we formatted the survey such that it could be adminis-
tered online using the Bristol Online Survey system
(https://www.onlinesurveys.ac.uk). The final version of
the questionnaire consisted of 47 questions (16 from
Roberts in part 1, and 31 in part 2), and it took 15–20
min to complete it.
Participant identification and recruitment
We invited members of the European Academy of Neur-
ology (EAN) and European Alzheimer’s Disease Consor-
tium (EADC). The EAN unites neurologists across Europe
and has members from 45 European national neurological
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societies and includes 800 individual neurologists (https://
www.eaneurology.org/). The EADC is a network of over 50
European centers that have a strong track record of clinical
and biomedical research in AD and related dementias
(http://www.eadc.info/sito/pagine/home.php).
We sent a link to the survey to members of the EAN
scientific panel on Dementia and Cognitive Disorders
(n = 74) and to EADC members (n = 140). We encour-
aged EAN and EADC members to share the survey to
other colleagues working in the dementia field but who
were not necessarily EAN or EADC members. We send
our first mail on 28 November 2014 and reminders on
12 and 19 December 2014. In addition, EAN members
were invited to complete the survey via a web link that
was provided in the November 2014 EAN newsblog,
which is sent to over 15,000 members of national neuro-
logical societies in Europe. The survey was live between
November 2014 and January 2015.
Analysis
Responses to survey items and demographics were expressed
as percentages. We tested differences in responses between
Table 1 Demographics
EAN/EADC AAN^
Age (mean (SD))* 50.0 (8.7) 54 (8.6)
Gender, n female/total (%) 26/84 (31%) 21%
Medical specialty, n (%)
- Neurology 74 (73%) 94.4%
- Geriatrics 9 (8.8%) 3.1%
- Psychiatry 9 (8.8%) 3.4%
- Neuropsychology 2 (1.9%) 4.4%
- Combination of the above 7 (6.9%) NA
Subspecialty training, n yes (%) 65 (63.7%) 59.6%
Years of experience, n (%) NA
- < 5 years 7 (6.9%)
- 5–10 years 15 (14.7%)
- 10–15 years 20 (19.6%)
- 15–20 years 20 (19.6%)
- > 20 years 40 (39.2%)
Organization, n (%)
- Solo practice 5 (4.9%) 30%
- Group practice 57 (59.9%) 48.4%
Single specialty group 1 (1.0%)
Multispecialty group 6 (5.9%)
University-based group 50 (49%)
- Hospital or clinic 38 (37.3%) 17.9%
Health care center 2 (2.0%)
Government hospital or clinic 28 (27.5%)
Other public or private hospital or clinical setting 8 (7.8%)
- Other 2 (2.0%) 3.6%
Number of respondents within a country, n NA
- Turkey, Denmark, Finland, Georgia, Ireland, Israel, Luxembourg, Poland 1
- Austria, Belgium, Bulgaria, Norway, Slovenia, Portugal 2
- Sweden, Greece, Romania, Netherlands, France, Italy, UK 3–6
- Czech Republic, Germany 7–9
- Spain 33
Abbreviation: NA not available
*Response from 75 subjects
^Only percentages reported
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the EAN/EADC and the AAN respondents regarding the
use of the MCI diagnosis. In a subgroup of respondents that
used the diagnosis of “Prodromal AD” or “MCI due to AD”
in clinical practice, we tested whether terminology, counsel-
ing, and management differed between patients with a diag-
nosis of prodromal AD/MCI due to AD and those without
that diagnosis. Group differences were tested by the chi-
square test. If a question had multiple responses, we used the
chi-square test for trend. A two-sided p value < 0.05 was con-
sidered statistically significant.
Results
Respondents
One hundred and two completed surveys were obtained,
of which 38 from EADC members (response rate 27%),
53 from the EAN (including 16 members of the Spanish
Association of Neurology), 3 from members of the Inter-
national Psychogeriatric Association (IPA), and 8 from
other or unknown sources. Demographic characteristics
of the respondents are shown in Table 1.
MCI
Terms and definitions of clinical diagnosis
Ninety-two percent of the respondents recognized MCI
as a clinical diagnosis. Of these, 85% differentiated be-
tween amnestic versus non-amnestic MCI forms and
65% used the subdivision of single versus multiple do-
main MCI. A minority of respondents used cognitive
impairment no dementia (CIND; 16%), age-associated
memory impairment (AAMI; 13%), or other terms (8%).
Clinical practice
Ninety-three percent of the respondents saw patients with
cognitive symptoms of mild severity routinely in practice. A
small proportion (6%) saw them once or twice per month
and 1% never. The most common terms to describe the
cognitive impairment to patients were MCI (75%), memory
problems (46%), and possibly early AD (45%).
Laboratory assessment was performed routinely in
92% of patients with MCI, neuropsychological testing in
82%, magnetic resonance imaging (MRI) in 65%, and
computed tomography in 42%. Less than 25% of respon-
dents performed routinely lumbar puncture, electroen-
cephalography (EEG), fludeoxyglucose positron emission
tomography (FDG-PET), single-photon emission com-
puted tomography (SPECT), or amyloid PET (Fig. 1).
Respondents routinely advised patients on mental
and physical exercise. Less than 50% of the respondents
discussed routinely diet and nutrition, alcohol intake
use of vitamins, and vascular risk factors (Table 2 and
Additional file 2: Figure S1). Most respondents rou-
tinely discussed with patients the need for follow-up
(89%) and the risk of AD in general terms (69%). Less
than 40% of the respondents discussed routinely nu-
meric estimates of AD, considerations in relation to
driving, potential to undertake research studies, support
service options available, potential benefits of advance
planning, and referral to the Alzheimer Association or
similar organizations (Table 2 and Fig. 2). A small pro-
portion of the respondents routinely prescribed cholin-
esterase inhibitors (21%), memantine (13%), or other
medications (e.g., vitamins or supplements, or antide-
pressants) (Table 2 and Additional file 2: Figure S1).
Attitudes towards MCI
More than 80% of the respondents agreed strongly or
somewhat with the statement that labeling cognitive
problems as MCI was helpful for patients and family
members and that labeling helps for future planning
and helps to engage in risk reduction. Furthermore, more
than 50% of the respondents agreed strongly or somewhat
with the statement that labeling aids planning of insurance
Fig. 1 Diagnostic investigations routinely performed in patients with MCI. Bars indicate frequencies (in %). Abbreviations: AD Alzheimer’s disease,
CT computed tomography, MRI magnetic resonance imaging, EEG electroencephalogram, SPECT single-photon emission computed tomography,
FDG-PET fludeoxyglucose positron emission tomography
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and finances and that certain medications can be helpful
for some patients. More than 50% of the respondents dis-
agreed strongly or somewhat with the statements that
MCI is usually better described as AD, that diagnosing
causes unnecessary worry for patients and family
members, that it is too difficult to diagnose MCI accur-
ately or reliably, and that it makes no sense to diagnose it
because there is no approved treatment. In a free text sec-
tion inviting open comment, the most common response
was that MCI is a broad symptomatic diagnosis without a
Table 2 Usual practice when seeing patients with cognitive symptoms of mild severity
Never Rarely Sometimes Routinely p value*
Patient counseling
- Diet and nutrition EAN/EADC 9 (8.8) 11 (10.8) 32 (31.4) 49 (48) 0.17
AAN 57 (13.6) 69 (16.4) 132 (31.5) 162 (38.5)
- Vitamins EAN/EADC 16 (15.7) 24 (23.5) 38 (37.3) 23 (22.5) 0.29
AAN 49 (11.6) 84 (20.1) 155 (36.9) 132 (31.4)
- Mental exercise EAN/EADC 1 (1) 4 (3.9) 13 (12.7) 83 (81.4) 0.41
AAN 13 (3.0) 21 (5.1) 71 (17.0) 315 (74.9)
- Physical exercise EAN/EADC 3 (2.9) 4 (3.9) 13 (12.7) 82 (80.4) 0.78
AAN 8 (1.8) 19 (4.5) 67 (15.9) 327 (77.8)
- Alcohol EAN/EADC 18 (17.6) 14 (13.7) 32 (31.4) 36 (35.3) **
Patient education
- Advance planning EAN/EADC 1 (1) 21 (20.6) 42 (41.2) 37 (36.3) 0.08
AAN 33 (7.9) 84 (20.0) 172 (41.0) 130 (31)
- Driving EAN/EADC 3 (2.9) 16 (15.7) 42 (41.2) 41 (40.2) 0.82
AAN 11 (2.6) 52 (12.3) 186 (44.2) 172 (40.9)
- Research studies EAN/EADC 2 (2) 12 (11.8) 47 (46.1) 40 (39.2) < 0.0001*
AAN 27 (6.4) 109 (26) 199 (47.4) 85 (20.2)
- Support services EAN/EADC 0 17 (16.7) 37 (36.3) 46 (45.1) 0.001*
AAN 18 (4.3) 92 (21.9) 195 (46.4) 115 (27.3)
- Recommendations for follow-up EAN/EADC 0 1(1) 8 (7.8) 91 (89.2) 0.75
AAN 0 5 (1.3) 44 (10.4) 371 (88.3)
- Risk of AD and related disorder
(general terms)
EAN/EADC 1 (1) 5 (4.9) 25 (24.5) 70 (68.6) 0.55
AAN 4 (1) 37 (8.9) 113 (27) 265 (63)
- Risk of AD and related disorders
(numeric estimates)
EAN/EADC 7 (6.9) 24 (23.5) 47 (46.1) 22 (21.6) 0.17
AAN 47 (11.1) 125 (29.8) 150 (35.7) 98 (23.4)
- Referral to Alzheimer’s association
or similar association
EAN/EADC 15 (14.7) 34 (33.3) 35 (34.3) 16 (15.7) 0.22
AAN 82 (19.5) 153 (36.5) 146 (34.7) 39 (9.3)
- Written summary letter of
findings for patient
EAN/EADC 9 (8.8) 13 (12.7) 25 (24.5) 54 (52.9) < 0.0001*
AAN 117 (27.8) 158 (37.6) 82 (19.6) 63 (14.9)
Medication prescribed
- Cholinesterase inhibitors EAN/EADC 28 (27.5) 16 (15.7) 35 (4.3) 21 (20.6) 0.01*
AAN 60 (14.3) 67 (15.9) 189 (45) 104 (24.8)
- Memantine EAN/EADC 64 (62.7) 14 (13.7) 7 (6.9) 13 (12.7) 0.0001*
AAN 147 (35.1) 108 (25.6) 129 (30.7) 36 (8.5)
- Other EAN/EADC 26 (25.5) 7 (6.9) 28 (27.5) 9 (8.8) 0.89
AAN 140 (33.3) 45 (10.8) 169 (40.2) 66 (15.7)
All data are N (%)
Abbreviations: EAN European Academy of Neurology, EADC European Alzheimer’s Disease Consortium, AAN American Academy of Neurology
*Differences in replies between EAN/EADC and AAN members (chi-square)
**Question not in the AAN survey
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description of the etiology and needed further investiga-
tion (Table 3 and Additional file 2: Figure S2).
Comparison with results from the AAN survey
Age and gender were similar between AAN and
EAN/EADC respondents. Compared to AAN respon-
dents, EAN/EADC respondents were less often neur-
ologist (73% versus 94%) and worked less often in a
solo practice (5% versus 30%) and more often in a
hospital setting (37% versus 18% (Table 1)). EAN/
EADC respondents more often saw patients with cog-
nitive symptoms of mild severity, discussed research
studies, and provided a written summary letter of the
findings than AAN respondents. EAN/EADC respon-
dents less commonly prescribed cholinesterase inhibi-
tors and memantine, and they less often agreed to
the statement that a diagnosis “causes unnecessary
worry to patients and family” (p < 0.0001 for all com-
parisons, Tables 2 and 3).
Prodromal AD/MCI due to AD
Research criteria and clinical practice
Sixty-eight percent of the respondents used the research
criteria for diagnosing prodromal AD/MCI due to AD
(22% used the IWG criteria, 35% the NIA-AA criteria, and
43% used both). Those who used the research criteria did
not differ in demographics or membership of EADC or
EAN, compared to non-users.
Reasons for the use of the research criteria were in-
creased certainty of diagnosis in almost 90%. Around
50% of the respondents used the research criteria to in-
crease possibilities to provide counseling and facilitation
of follow-up planning and to start medical intervention.
Less than 50% of the respondents used the criteria to
respond to patients’ wish for a diagnosis and to facilitate
selection for clinical trial selection or observational
studies.
Thirty-two percent of the respondents did not use the
research criteria. The most common reasons were lack
of standardized measurements and cut-off values (42%),
lack of treatment possibilities (42%), and lack of implica-
tion on a single-level case (33%). In less than 30% of the
respondents, there was an inability to perform a bio-
marker measurement, a concern that the diagnosis
might upset patients and their family; the lack of inclu-
sion in national guidelines, or the lack of added value in
diagnosing prodromal AD/MCI due to AD over a diag-
nosis of MCI.
Of the criteria users, 49% applied the research cri-
teria only in a subset. This group applied criteria if
they perceived a clinical need (38%) or if the patient
wished to know (26%). Other reasons indicated in the
open text field, were younger age, and selection of
subjects for research. Seventy percent of the respon-
dents always disclosed the diagnosis. The most com-
mon reason (50%) not to disclose diagnosis was the
wish of patients not to know. Other reasons not to
disclose the diagnosis were diagnostic uncertainty and
fear that the diagnosis might upset patients or their
family. When the diagnosis was not disclosed, infor-
mation was still used to plan future care by 75%.
Biomarkers always or often used to define prodromal
AD/MCI due to AD were MRI measures of the medial
temporal atrophy (MTA, 75%), CSF amyloid beta 1–42,
or tau (52–55%). Less than 30% used FDG-PET, SPECT,
or amyloid PET (Fig. 3).
Fig. 2 Topics that are routinely discussed with patients with MCI. Blue bars are frequencies (in %) of respondents of EAN/EADC who discuss
routinely the above topics. Red bars are frequencies (in %) of respondents of the AAN survey. Abbreviations: EAN European Academy of
Neurology, EADC European Alzheimer’s Disease Consortium, AAN American Academy of Neurology. Difference frequencies between EAN/EADC
and AAN members were tested using chi-square. *p < 0.01, **p < 0.0001
Bertens et al. Alzheimer's Research & Therapy           (2019) 11:74 Page 6 of 12
The use of research criteria appeared to influence the
communication towards patients. The term “MCI” was
less often used and terminology including “possible early
AD” more often compared to the use of MCI as diagnos-
tic label (p = 0.001). When patients met the research cri-
teria, respondents more often used the term “possible
early AD” and “early AD” (p < 0.0001) and less often
patients were told they had “memory problems or diffi-
culties” or “did not have dementia or AD” compared to
subjects not meeting the criteria (p < 0.0001).
Counseling by respondents on diet and nutrition, vi-
tamins, mental exercise, physical exercise, and alcohol
did not differ between patients with or without criteria
for prodromal AD/MCI due to AD. However, patients
who met the criteria for prodromal AD/MCI due to
AD respondents were more often counseled on the
need for follow-up, risk for AD in general terms ad-
vanced planning, driving, participation in research
studies, availability of support services, and access to
other support organizations and were more often pre-
scribed cholinesterase inhibitors compared to patients
who did not meet the criteria (Table 4 and Additional file 2:
Figure S3).
Attitudes towards prodromal AD/MCI due to AD
In the total group, over 80% of the respondents
agreed strongly or somewhat to the statement that a
diagnosis of prodromal AD/MCI due to AD was help-
ful for labeling the problem for patients and family
members, was helpful for inclusion into clinical trials,
aided physicians to plan for follow-up, involved pa-
tients in future planning, and motivated patients to
engage in risk reduction activities. It was also fre-
quently reported (62–76%) that a diagnosis could help
family and patients with financial or insurance plan-
ning and could help in the decision to start
medication.
The majority of all respondents strongly or some-
what disagreed with the statement that diagnosing
prodromal AD/MCI due to AD has no added value
over a diagnosis of MCI (70%). There was also con-
siderable disagreement with the suggestions that it is
too difficult to diagnose it accurately or reliably
(69%), that it causes unnecessary worry for patients
and family members (69%), and that there is no ap-
proved treatment so it does not make sense to diag-
nose it (73%) (Table 5 and Fig. 4).
Table 3 Perceptions of benefits, drawbacks, and limitations of MCI as a clinical diagnosis
Benefits Strongly
agree
Somewhat
agree
Neither agree
or disagree
Somewhat
disagree
Strongly
disagree
p value
- Labeling the problem is helpful for
patients and family members
EAN/EADC 52 (51) 38 (37.3) 7 (6.9) 2 (2) 3 (2.9) 0.12
AAN 191 (45.5) 192 (45.7) 24 (5.6) 11 (2.7) 2 (0.5)
- A diagnosis is useful so the patient can
be more involved in planning for the future
EAN/EADC 44 (43.1) 41 (40.2) 8 (7.8) 5 (4.9) 4 (3.9) 0.15
AAN 184 (43.8) 180 (42.8) 37 (8.8) 16 (3.9) 3(0.7)
- A diagnosis can be useful in motivating
the patient to engage in risk reduction activities
EAN/EADC 43 (42.2) 42 (41.2) 9 (8.8) 6 (5.9) 2 (2) 0.61
AAN 148 (35.2) 207 (49.4) 39 (9.3) 21 (4.9) 5 (1.2)
- A diagnosis helps the family with
insurance planning
EAN/EADC 23 (22.5) 30 (29.4) 32 (31.4) 9 (8.8) 8 (7.8) 0.18
AAN 90 (21.5) 143 (34.1) 143 (34.1) 31 (7.3) 12 (2.9)
- A diagnosis helps the family with
financial planning
EAN/EADC 25 (24.5) 41 (40.2) 27 (26.5) 4 (3.9) 5 (4.9) 0.35
AAN 121(28.7) 183 (43.6) 93 (22.1) 15 (3.6) 8 (1.9)
- Certain medications can be useful for
treating some patients
EAN/EADC 16 (15.7) 39 (38.2) 18 (17.6) 16 (15.7) 13 (12.7) 0.034
AAN 76 (18.0) 199 (47.3) 75 (17.8) 49 (11.7) 21 (5.1)
Drawbacks and limitations
- Diagnosing causes unnecessary worry
for patients and family members
EAN/EADC 8 (7.8) 12 (11.8) 11 (10.8) 28 (27.5) 43 (42.2) 0.0001*
AAN 8 (2.0) 74 (17.6) 75 (17.8) 155 (36.8) 109 (25.9)
- There is no approved treatment so it
does not make sense to diagnose
EAN/EADC 6 (5.9) 0 6 (5.9) 25 (24.5) 65 (63.7) 0.02*
AAN 11 (2.7) 24 (5.6) 33 (7.8) 130 (31.0) 222 (52.9)
- It is too difficult to diagnose accurately
or reliably
EAN/EADC 4 (3.9) 10 (9.8) 9 (8.8) 35 (34.3) 44 (43.1) 0.013*
AAN 8 (2.0) 88 (21.0) 53 (12.7) 147 (34.9) 124 (29.5)
- MCI is usually better described as early
Alzheimer’s disease
EAN/EADC 8 (7.8) 13 (12.7) 23 (22.5) 30 (29.4) 28 (27.5) 0.91
AAN 26 (6.1) 60 (14.4) 87 (20.8) 138 (32.8) 109 (25.9)
All data are N (%)
Abbreviations: EAN European Academy of Neurology, EADC European Alzheimer’s Disease Consortium, AAN American Academy of Neurology
*Differences between answers between EAN/EADC and AAN members were tested using chi-square and are indicated with a p value
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Discussion
According to this survey, the term MCI was widely used
and considered to represent a useful clinical entity. MCI
definitions, communication with patients, management,
and attitudes towards the concept were, with a few ex-
ceptions, similar to that of AAN members in a previous
study. The novel research criteria for prodromal AD/
MCI due to AD were used by 68% of the respondents, of
whom 51% used the criteria in all subjects with MCI.
The use of the research criteria influenced the commu-
nication with and management of subjects with MCI.
MCI was widely used as a clinical diagnosis and also
referred to in communications with patients and their
family. To diagnose MCI, respondents performed neuro-
psychological testing, while laboratory assessments, as
well as MRI or CT imaging, were performed in the ma-
jority of the cases, which is in agreement with the EAN
guidelines for the assessment of AD [10]. Respondents
perceived that labeling the problem outweighed any
negative effect but still 20% agreed with the statement
that MCI would cause unnecessary worry for patients
and family. Other reported benefits were a better plan-
ning for future and motivation of patients to engage risk
reduction. Remarkably, prescription of cholinesterase
inhibitors, memantine, vitamins, and supplements was
relatively common, although there is no evidence of effi-
cacy for these treatments in MCI.
The responses of the EAN/EADC members were gen-
erally similar to those of AAN members, despite the
time interval of the studies. A major difference was that
EAN/EADC respondents less frequently prescribed cho-
linesterase inhibitors and memantine, compared to AAN
respondents. Since such prescription of dementia medi-
cations in subjects with MCI is off-label use both in
Europe and the USA, AAN members might be more
convinced that these medications are of benefit.
Despite being research criteria, the majority of respon-
dents used prodromal AD/MCI due to AD criteria in
clinical practice. The main reason given for this use was
that the criteria increased the certainty of AD diagnosis.
Only 55% often or routinely used an amyloid marker
indicating that, in the majority of the cases, an injury
marker was used for diagnosis. This is consistent with
the NIA-AA criteria of intermediate likelihood and the
IWG-1 criteria, but not with the IWG-2 criteria, as these
consider amyloid markers as a core diagnostic feature.
Yet, IWG-2 criteria were published only a few months
before we performed our survey and therefore were
unlikely to have been incorporated into clinical practice.
The use of either an amyloid or injury marker may result
in heterogeneity among subjects with “prodromal AD/
MCI due to AD” as there is only moderate overlap be-
tween amyloid and injury markers since they become ab-
normal in different stages of the disease and are
supposed to reflect disease processes [11]. Not using
amyloid markers may result from lack of awareness of
the different diagnostic properties of amyloid and injury
markers, lack of training of physicians to perform a lum-
bar puncture, or lack of possibilities to perform cerebro-
spinal assessment or amyloid imaging. Moreover,
assessment of amyloid pathology is often not mentioned
in national guidelines on dementia in Europe nor is it
reimbursed. At the time of our survey in 2014, another
survey showed that of the 19 countries that were included
in our study only 8 had national guidelines that discussed
CSF analysis in the assessment of cognitive disorders [12].
CSF analysis was reimbursed in 11 of the 19 countries.
Forty-nine percent of the respondents who applied the
research criteria did assessments in a subset of patients
depending on the clinical need and the wishes of patients.
The latter criterion for selection underlines the import-
ance for shared decision-making, since, in light of the lack
Fig. 3 Use of biomarkers for scoring the research criteria. Bars indicate responders (in %) that often or always performed diagnostic assessment of
the above-mentioned tests. Abbreviations: MTA medial temporal atrophy, MRI magnetic resonance imaging, CSF cerebrospinal fluid, abeta
amyloid beta, FDG-PET fludeoxyglucose positron emission tomography, SPECT single-photon emission computed tomography, PET positron
emission tomography
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of treatment possibilities, it is important to inform pa-
tients on the benefits and possible drawbacks of making a
diagnosis [9]. In line with this, 15% of criteria users did
not always disclose diagnosis if the patient or family mem-
bers did not want to know.
Using research criteria had a major influence on the way
patients were communicated with and their management,
such as prescription of cholinesterase inhibitors. Despite of
the fact that the criteria are meant for research use, respon-
dents apparently found them clinically helpful. Irrespective
Table 4 Usual practice when seeing patients with or without prodromal AD/MCI due to AD
Never Rarely Sometimes Routinely p value*
Patient counseling
- Diet and nutrition Prodromal AD 7 (11) 5 (8) 25 (38) 28 (43) 0.97
No prodromal AD 8 (12) 6 (9) 24 (37) 27 (42)
- Vitamins Prodromal AD 15 (23) 19 (29) 23 (35) 8 (12) 0.99
No prodromal AD 14 (22) 19 (29) 24 (37) 8 (12)
- Mental exercise Prodromal AD 2 (3) 2 (3) 7 (10) 56 (84) 0.45
No prodromal AD 3 (4) 5 (8) 10 (15) 48 (73)
- Physical exercise Prodromal AD 1 (1) 1 (1) 10 (15) 55 (82) 0.31
No prodromal AD 1 (2) 4 (6) 15 (23) 46 (69)
- Alcohol Prodromal AD 10 (15) 13 (20) 22 (33) 21 (32) 0.95
No prodromal AD 8 (13) 12 (19) 24 (38) 20 (30)
Patient education
- Advance planning Prodromal AD 0 6 (9) 28 (41) 34 (50) 0.0001*
No prodromal AD 6 (9) 20 (30) 26 (39) 14 (21)
- Driving Prodromal AD 0 5 (7) 27 (40) 36 (53) 0.0001*
No prodromal AD 5 (8) 18 (27) 28 (42) 15 (23)
- Research studies Prodromal AD 0 5 (7) 32 (47) 31 (46) 0.0001*
No prodromal AD 6 (9) 25 (38) 26 (39) 9 (14)
- Support services Prodromal AD 0 11 (16) 24 (36) 32 (48) 0.003*
No prodromal AD 4 (6) 25 (38) 19 (29) 18 (27)
- Recommendations for follow-up Prodromal AD 0 2 (3) 4 (6) 61 (91) 0.0001*
No prodromal AD 0 10 (15) 15 (22) 42 (63)
- Risk of AD and related disorder (general terms) Prodromal AD 0 1 (2) 23 (34) 42 (64) 0.0001*
No prodromal AD 3 (5) 17 (27) 22 (34) 22 (34)
- Risk of related disorders (numeric estimates) Prodromal AD 9 (13) 19 (28) 27 (40) 12 (18) 0.33
No prodromal AD 13 (20) 24 (38) 19 (30) 8 (12)
- Referral to Alzheimer’s association or similar organization Prodromal AD 6 (9) 16 (24) 30 (46) 14 (21) 0.0001*
No prodromal AD 29 (45) 20 (31) 12 (18) 4 (6)
- Written summary letter of findings for patient and family Prodromal AD 6 (9) 6 (9) 18 (27) 37 (55) 0.91
No prodromal AD 6 (9) 8 (12) 19 (29) 33 (50)
Medication prescribed
- Cholinesterase inhibitors Prodromal AD 9 (13) 8 (12) 26 (39) 24 (36) 0.0001*
No prodromal AD 40 (61) 18 (27) 6 (9) 2 (3)
- Memantine Prodromal AD 44 (66) 13 (19) 7 (11) 3 (4) 0.30
No prodromal AD 52 (79) 10 (15) 3 (4) 1 (2)
- Other Prodromal AD 12 (32) 5 (13) 16 (42) 5 (13) 0.46
No prodromal AD 13 (37) 2 (6) 18 (51) 2 (6)
All data are N (%)
Abbreviation: AD Alzheimer’s disease
*Differences in replies between patients meeting criteria for prodromal AD/MCI due to AD and patients not meeting criteria for prodromal AD/MCI due to
AD (chi-square)
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of the application of the research criteria, all respondents
perceived more benefits than drawbacks using the criteria
in clinical practice.
This is in accordance with a previously performed
EADC survey where respondents claimed to perceive
high diagnostic confidence using AD biomarkers and clinical
studies that use of amyloid biomarkers increased diagnostic
confidence and impacted management [9, 13, 14].
In 2018, the NIA-AA consortium published an update
to the NIA-AA criteria, referred to as a research frame-
work [15]. It extends the NIA-AA criteria by basing the
diagnosis of AD on amyloid, tau, and neuronal injury
Table 5 Perceptions of benefits, drawbacks, and limitations of prodromal AD/MCI due to AD in clinical practice
Strongly
agree
Somewhat
agree
Neither agree or
disagree
Somewhat
disagree
Strongly
disagree
Benefits
- Labeling the problem is helpful for patients and family members 53 (52) 33 (32) 6 (6) 4 (4) 6 (6)
- A diagnosis is useful so the patient can be more involved in
planning for the future
45 (44) 38 (37) 10 (10) 6 (6) 3 (3)
- A diagnosis can be useful in motivating the patient to engage in
risk reduction activities
43 (42) 40 (39) 10 (10) 5 (5) 4 (4)
- A diagnosis helps the family with insurance planning 28 (27) 35 (34) 27 (26) 6 (6) 6 (6)
- A diagnosis helps the family with financial planning 30 (29) 47 (46) 16 (16) 4 (4) 5 (5)
- A diagnosis can be useful for including patients in clinical trials 71 (70) 23 (23) 5 (5) 3 (3) 0
- Certain medications can be useful for treating some patients 26 (25) 39 (38) 13 (13) 10 (10) 14 (14)
- A diagnosis is useful for the physician to plan the follow-up 58 (57) 29 (28) 7 (7) 5 (5) 3 (3)
Drawbacks and limitations
- Diagnosing causes unnecessary worry for patients and family
members
4 (4) 14 (14) 14 (14) 36 (35) 34 (33)
- There is no approved treatment so it does not make sense to
diagnose
13 (13) 3 (3) 12 (12) 23 (23) 51 (50)
- It is too difficult to diagnose accurately or reliably 4 (4) 21 (21) 7 (7) 30 (30) 40 (39)
- A diagnosis has no added value over the diagnosis of MCI 8 (8) 9 (9) 14 (14) 21 (21) 50 (49)
All data are N (%)
Abbreviation: MCI mild cognitive impairment
Fig. 4 Topics of discussion in patients with and without prodromal AD. Frequency (%) of respondents that routinely discussed the above topics
in patients with “prodromal AD” (blue column) or “no prodromal AD” (red column). Difference frequencies between “prodromal AD” and “no
prodromal AD” were tested using chi-square. *p < 0.01, **p < 0.0001
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markers (ATN staging). Although conceptually the frame-
work is similar to the NIA-AA and IWG-2 criteria as it
defines amyloid pathology as necessary for the diagnosis
of AD, the combination of both tau and injury markers
may be more difficult to implement in clinical practice as
the number of diagnostic categories increases.
A limitation of this comparative study was that the
EAN/EADC survey was administered 5 years after the
AAN survey. Nevertheless, the results were comparable
across the two surveys but we cannot exclude the possi-
bility that over time the attitudes towards MCI have
changed among AAN members. Another possible limita-
tion was the EAN/EADC survey was held among clini-
cians with a special interest in neurodegenerative
disorders and mainly working at university hospitals,
such that the responses may not be wholly generalizable
to the broader community of clinicians. We sent our
survey to members of the EADC and the EAN scientific
panel on Dementia and Cognitive Disorders, which have
a research interest in dementing disorders, which limits
the generalizability of the findings. Because EADC and
EAN members overlap and because we distributed the
survey through the EAN newsletter, which is received
also by neurologists not working in the dementia field,
no response rate could be calculated. As we expanded
upon the original AAN survey on MCI by including a
second part focusing on the research criteria, this in-
creased the length of the survey and may have increased
levels of non-response. Another limitation that may
argue against representativeness is that 30% of our re-
spondents were from Spain. However, post hoc analysis
showed only a few differences between respondents from
Spain compared to other respondents. Finally, question-
naires measured opinions and actual use of the criteria
may be different. Our survey highlights that both the
MCI and prodromal AD/MCI due to AD criteria are
considered clinically useful. Our survey indicated several
barriers for the use of the criteria in clinical practice
such as lack of standardized measurements and cut-off
values of biomarkers [6–8, 15]. This will become even
more problematic with the NIA-AA research framework
as more biomarkers now can be used for the diagnosis,
for which often no established cut-points are available,
such as CSF neurofilament light. Moreover, there was
variability in type of diagnostic tests used and patient
management between clinicians. These findings high-
light the need for an update of national and international
guidelines on the diagnosis and management of prede-
mentia AD and communication to patients. This should
take into account cultural background, the age, religious
background, and education of patients [16].
In our study, we focused on the opinion of clinicians;
however, it will be crucial to assess the opinions and
needs of patients in future studies as well.
Conclusions
Our survey showed that both the MCI and prodromal
AD/MCI due to AD criteria are considered clinically use-
ful and that the diagnosis influenced the management of
patients meeting these criteria. However, clinicians dif-
fered in the tests used to make the diagnosis and in the
management of the patients. This highlights the need for
standardized national and international guidelines for the
diagnosis and management of predementia AD.
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